| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Physiology, University of Melbourne, Victoria, Australia
Interleukin (IL)-15, a cytokine expressed in skeletal muscle, has been shown to have muscle anabolic effects in vitro and to slow muscle wasting in rats with cancer cachexia. Whether IL-15 has therapeutic potential for diseases such as Duchenne muscular dystrophy (DMD) is unknown. We examined whether IL-15 administration could ameliorate the dystrophic pathology in the diaphragm muscle of the mdx mouse, an animal model for DMD. Four weeks of IL-15 treatment improved diaphragm strength, a highly significant finding because respiratory function is a mortality predictor in DMD. Enhanced diaphragm function was associated with increased muscle fiber cross-sectional area and decreased collagen infiltration. IL-15 administration was not associated with changes in T-cell populations or alterations in specific components of the ubiquitin proteasome pathway. To determine the effects of IL-15 on myofiber regeneration, muscles of IL-15-treated and untreated wild-type mice were injured myotoxically, and their functional recovery was assessed. IL-15 had a mild anabolic effect, increasing fiber cross-sectional area after 2 and 6 days but not after 10 days. Our findings demonstrate that IL-15 administration improves the pathophysiology of dystrophic muscle and highlight a possible therapeutic role for IL-15 in the treatment of neuromuscular disorders especially in which muscle wasting is indicated.
This article has been cited by other articles:
 |
|
 |
|
  J. G. Ryall, J. D. Schertzer, T. M. Alabakis, S. M. Gehrig, D. R. Plant, and G. S. Lynch Intramuscular {beta}2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury J Appl Physiol, July 1, 2008; 105(1): 165 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Quinn Interleukin-15: A muscle-derived cytokine regulating fat-to-lean body composition J Anim Sci, April 1, 2008; 86(14_suppl): E75 - E83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Stupka, J. D. Schertzer, R. Bassel-Duby, E. N. Olson, and G. S. Lynch Stimulation of calcineurin A{alpha} activity attenuates muscle pathophysiology in mdx dystrophic mice Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R983 - R992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Schertzer, S. M. Gehrig, J. G. Ryall, and G. S. Lynch Modulation of Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein Interactions Enhances Skeletal Muscle Regeneration and Ameliorates the Dystrophic Pathology in mdx Mice Am. J. Pathol., October 1, 2007; 171(4): 1180 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Pistilli, P. M. Siu, and S. E. Alway Interleukin-15 responses to aging and unloading-induced skeletal muscle atrophy Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1298 - C1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Schertzer, J. G. Ryall, and G. S. Lynch Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E499 - E505. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
